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Background/aim: This study aims to identify the role of synovial fluid levels of a disintegrin and metalloproteinase with thrombospondin
motifs 9 (ADAMTS9) and a disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4) for the prediction of
intraarticular steroid injection success in knee osteoarthritis (OA).
Material and methods: A total of eighty-four advanced stage knee OA patients (42 with stage 3 OA and 42 with stage 4 OA) were enrolled
in the study. Baseline and posttreatment outcomes were determined using Western Ontario and McMaster Universities Osteoarthritis
Index (WOMAC). Pretreatment synovial fluid ADAMTS9 and ADAMTS4 levels were measured by enzyme linked immunosorbent
assay (ELISA). ‘’Total WOMAC score regression of 18% and above’’ was taken as a minimal clinically important difference (MCID)
to indicate improvement. Determining the best predictors of intraarticular steroid injection success in both groups was evaluated by
multiple logistic regression analyses.
Results: Synovial fluid ADAMTS9 levels were significantly lower in the stage 4 OA group when compared with the stage 3 group. The
level of synovial fluid ADAMTS9 was statistically significantly lower in the WOMAC score percent change ≥18% than the WOMAC
score percent change <18% group in Stage 3 OA group (P = 0.026). Decreasing synovial fluid ADAMTS9 levels (odds ratio (OR): 0.625,
95% confidence interval (CI): 0.437–0.893) were found to be predictive for the WOMAC score percent change ≥18 in all OA patients
(P = 0.010). Decreasing ADAMTS9 levels in synovial fluid (OR: 0.602; 95% CI = 0.372–0.974) were predictive for MCID in stage 3 OA
patients (P = 0.039).
Conclusion: The lower levels of ADAMTS9 in synovial fluid may be used in conjunction with high WOMAC scores in the prediction
of intraarticular steroid injection success and advanced stage knee OA patients.
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1. Introduction
Knee osteoarthritis (OA) is a destructive joint disease
in which joint manifestations include progressive loss of
cartilage, cartilage calcification, osteophyte formation,
and subchondral bone remodelling. Osteoarthritis is
graded according to radiological findings of changes in
the joints. The Kellgren and Lawrence (K&L) scoring
system is used to denote the radiological stage in OA. In
advanced stages of OA, progressive changes occur due to
cartilage degradation [1]. The extracellular matrix (ECM)
of cartilage consists of type 2 collagen and aggrecan,
which is a significant proteoglycan [1]. Progressive
changes in cartilage in OA are dependent on active cell
processes mediated by cytokines and proteases [1]. The
role of synovial inflammation in the progression of OA
is well known [2]. Several studies demonstrated that
inflammation of the synovial membrane played a role in

the progress of joint degeneration by increasing the release
of proteases, such as matrix metalloproteinases and a
disintegrin and metalloproteinase with thrombospondin
motifs (ADAMTS), in the fibroblasts of cartilage [3,4].
Members of the ADAMTS family, especially ADAMTS4
and ADAMTS9 are already known to bind and degrade
ECM components and contribute to joint destruction
processes in arthritis [5]. Zhang et al. [6] showed that
ADAMTS4 levels in synovial fluid were significantly
lower in late-stage OA than in early-stage OA. Peng et al.
[7] reported that ADAMTS4 in synovial fluid might be a
potential biomarker for cartilage degeneration. Previously,
the aggrecanases ADAMTS4 and ADAMTS5 were shown
to contribute to cartilage destruction and to be responsible
for aggrecan degradation, especially in patients with earlystage OA [8]. Gok et al. [9] suggested that the cytosine
adenine (CA) repeat polymorphism of the ADAMTS9 gene
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could be used to determine the radiological progression of
OA.
Although recent studies have already shown that
ADAMTS4 and ADAMTS9 are involved in cartilage
destruction in OA [10,11], the possible role of these
matrix metalloproteinases in OA progression and their
utility in the evaluation of treatment success remains
unclear. This study aimed to determine the significance
of synovial fluid ADAMTS4 and ADAMTS9 levels in OA
progression, particularly in the assessment of the response
to intraarticular steroid injection in advanced stage OA
patients.
2. Materials and methods
Eighty-four advanced stage knee OA female patients (42
with stage 3 OA and 42 with stage 4 OA) with matching
body mass index (BMI) were recruited consecutively from
the outpatient clinic of Konya Beyşehir State Hospital in
2018. The diagnosis of knee OA was determined according
to the radiographic features. The radiological stage was
based on the K&L scale, which is accepted as a reference
standard of the World Health Organization. It requires the
presence of all five radiological criteria: osteophytes on the
joint side, periarticular ossicles, joint area narrowing (JSN),
small pseudocyst regions within the subchondral bone
and a change in the formation of the bone ends. Inclusion
criteria of OA patients: patients with radiological features
(stage 3 medium multiple osteophytes, JSN, minimal
sclerosis, and deformity of bone ends) and stage 4 (giant
osteophytes, evident JSN, severe sclerosis, and deformity
of bone ends) [12], women who have not received any
intraarticular and/or systemic OA therapy before and a
BMI between 30 kg/m2 and 18 kg/m2.
Exclusion criteria: patients with other knee joint
diseases (arthroscopic anterior cruciate ligament
reconstruction, meniscus angioplasty or arthroscopy, nonOA group), infectious diseases, septic arthritis, obesity,
neurological or neuromuscular diseases, bone tumours,
osteoporosis or trauma related fractures, diabetes
mellitus, Addison’s disease, immune system disorder,
rheumatological diseases and previous use of systemic
steroids and intraarticular hyaluronic acid injections.
Also, OA women who did not comply with stage 3 and
stage 4 criteria, that is, no changes in X-ray or changes in
only osteophyte or JSN, were not included in the study.
All participants provided written informed consent,
and the study ethics committee approval was obtained from
the local Ethical Committee of the University (approval
date/number: 06.02.2018/005-006). Clinical examination
was performed, and anthropometric measurements,
concomitant diseases (diabetes, hypertension, and
cardiovascular diseases) were recorded for all participants
included in the study. Knee function was assessed before

and 1 month after the treatment with intraarticular
steroid injection, using the Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC).
The WOMAC score is composed of 24 parameters that
include pain (score range: 0–20), stiffness (score range:
0–8), and functional impairment (score range: 0–68) [13].
Improvement in the WOMAC score after intraarticular
injection was assessed within an average of one to 3 months.
‘’Total WOMAC score regression of 18% and above’’ was
taken as a minimal clinically important difference (MCID)
to indicate improvement [14].
Only advanced stage OA patients who received an
intraarticular injection of the steroid methylprednisolone
acetate (40 mg to 1 mL) were included in the study.
Patients managed with surgical treatment were excluded.
Knee joint synovial fluid samples were obtained using
sterile needles. The samples were stored at –80 °C until the
day of analysis.
Synovial fluid levels of ADAMTS4 and ADAMTS9 were
analyzed using Eastbiopharm branded human ADAMTS4
and ADAMTS9 enzyme linked immunosorbent assay
(ELISA) kit with an immunoassay device (Immulite 2000)
and presented in pg/mL and ng/mL, respectively. The
blood reference range of the ADAMTS9 assay kit is 5–400
ng/mL, and the blood reference range of the ADAMTS4
assay kit is 5–1000 pg/mL. The intraassay and interassay
coefficients of variation of the kit were lower than 10% and
12%, respectively.
2.1. Statistical analysis
Data analysis was performed using SPSS for Windows,
version 22 (SPSS Inc., Chicago, IL, USA). Whether the
distributions of continuous variables were normal or not
was determined using the Kolmogorov–Smirnov test,
homogeneity of variances was evaluated using the Levene
test. Continuous variables were shown as mean ± standard
deviation (SD) or median (min–max), where applicable.
While Student’s t-test compared the mean differences
between groups, the Mann–Whitney U test was applied
for comparisons of the median values. Patients with
advanced OA, according to the K&L scale, were grouped
into stage 3 and stage 4 OA. The optimal cutoff points of
synovial fluid ADAMTS9 levels in advanced stage OA
cases were evaluated by receiver operating characteristic
(ROC) analyses, calculating the area under the curve
(AUC) as giving the maximum sum of sensitivity and
specificity for the variables test. Stage 3 and stage 4 groups
were subgrouped into those with a WOMAC score percent
change ≥18% and a WOMAC score percent change <18%.
Synovial fluid ADAMTS9, synovial fluid ADAMTS4 levels
and other variables were compared with Student’s t-test,
responding and not responding to the improvement
in WOMAC score in stage 3 and stage 4 groups. Also,
categorical comparisons were performed using the χ2-test.
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Finally, multiple logistic regression analysis was performed
separately in stage 3, stage 4, and all advanced stage knee
OA patients to determine the effect of independent
variables associated with response to intraarticular
therapy. Adjusted odds ratios (ORs) and 95% confidence
intervals (CI) were calculated for each variable. A P-value
of less than 0.05 was considered statistically significant.
3. Results
A total of 84 BMI matched OA patients with advanced
stage disease (stage 3, n = 42; stage 4, n = 42) were
enrolled in the study. Their baseline anthropometric and
biochemical characteristics are given in Table 1. The mean
age of the patients with stage 3 OA was 62.38 ± 6.78 years,
and patients with stage 4 OA was 67.64 ± 5.63 years. The
mean age of the patients with stage 4 OA was significantly
higher than the stage 3 OA group (P < 0.001). There were
no statistically significant differences among smokers in
the groups (P = 0.766).
Synovial fluid ADAMTS9 levels were 5.92 ± 1.94
ng/mL in stage 3 OA and 5.02 ± 1.35 ng/mL in stage 4
OA cases (Figure 1). The patients with stage 4 OA had
significantly lower levels of ADAMTS9 when compared
with stage 3 OA group (P = 0.017). WOMAC scores before
intraarticular injection were 82.12 ± 6.18 and 65.21 ±
16.26. WOMAC scores after intraarticular injection were
67.26 ± 7.21 and 53.19 ± 12.72 respectively for stage 3
and stage 4 OA patients. WOMAC scores before and after
intraarticular injection were significantly higher in the
stage 3 OA group compared to the stage 4 OA group (P

< 0.001and P < 0.001). Synovial fluid ADAMTS4 levels
were 128.51 ± 27.79 pg/mL and 131,84 ± 35.47 pg/mL
respectively in stage 3 and 4 OA groups. There were no
statistically significant differences among synovial fluid
ADAMTS4, WOMAC score change and concomitant
diseases (hypertension,cardiovascular diseases, and
diabetes ) between groups (Table 1).
Synovial fluid ADAMTS9 levels were again evaluated
with ROC analysis (Figure 2); cutoff levels were determined,
and AUC values were calculated. The AUC, best cutoff
values, sensitivity, and specificity for distinguishing the
groups for each parameter are given in Table 2. Synovial
fluid ADAMTS9 levels were found to be statistically
significant. When the groups that responded and did not
respond to the treatment were compared within stage
3 and stage 4, the synovial fluid ADAMTS9 levels were
5.04 ± 1.44 ng/mL in the WOMAC score percent change
≥18% group, and 6.43 ± 2.01 ng/mL in the WOMAC score
percent change <18% group.
The level of synovial fluid ADAMTS9 was statistically
significantly lower in the WOMAC score percent change
≥18% than the WOMAC score percent change <18%
group in stage 3 OA (P = 0.026). There were no statistically
significant differences among age, smoking, synovial
fluid ADAMTS4, and concomitant diseases between the
groups in stage 3 (Table 3). Age, smoking, synovial fluid
ADAMTS9, synovial fluid ADAMTS4, and concomitant
diseases were not statistically different between WOMAC
score percent change ≥18% and WOMAC score percent
change <18% in stage 4 (Table 4).

Table 1. Baseline characteristics and laboratory parameters of stage 3 and stage 4 OA patients.
Stage 3 OA
n = 42

Stage 4 OA
n = 42

P-value*

Age (years)

62.38 ± 6.78

67.64 ± 5.63

<0.001

Smoking

7(16.7%)

8 (19.0%)

0.776

Synovial fluid ADAMTS4 (pg/mL)

128.51 ± 27.79

131.84 ± 35.47

0.633

Synovial fluid ADAMTS9 (ng/mL)
WOMAC score

5.92 ± 1.94

5.02 ± 1.35

0.017

Total score (before intraarticular injection)

82.12 ± 6.18

65.21± 16.26

0.001

Total score (after intraarticular injection)

67.26± 7.21

53.19± 12.72

0.001

13[5–31]

9 [1–40]

0.099

Hypertension and cardiovascular diseases

7(16.7%)

11 (26.2%)

Diabetes

4 (9.5%)

4(9.5%)

No additional diseases

31 (73.8%)

27 (64.3%)

WOMAC score change (median[min–max])
Concomitant
diseases

0.559

*; a P-value of < 0.05 is considered statisticallysignificant. Independent sample t-test, P-value: Statistically significant difference between
stage 3 and stage 4 knee osteoarthritis, ADAMTS4; A disintegrin and metalloproteinase with thrombospondin motif 4, ADAMTS9;
A disintegrin and metalloproteinase with thrombospondin motif 9, WOMAC score; Western Ontario and McMaster Universities
Osteoarthritis Score.
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Figure 1. Synovial fluid ADAMTS9 levels in stage 3 and stage 4 OA patients.

Also, logistic regression analysis was performed
again to determine the variables associated with an 18%
improvement in the WOMAC (MCID) of intraarticular
steroid injection treatment in stage 3 and stage 4 OA
patients, respectively. Only decreasing ADAMTS9 levels
in synovial fluid (OR: 0.602; 95% CI = 0.372–0.974) were
predictive for MCID in stage 3 OA patients (P = 0.039)
(Table 6). Age, smoking, synovial fluid ADAMTS9,
synovial fluid ADAMTS4, and concomitant diseases were
not statistically associated with MCID in stage 4 (Table 6).

Figure 2. Synovial fluid ADAMTS9 ROC curve in OA patients.

3.1. Multivariate analysis
At first, logistic regression analysis was performed
to determine the variables associated with an 18%
improvement in the WOMAC (MCID) of intraarticular
steroid injection in all OA patients. Decreasing synovial
fluid ADAMTS9 levels (OR: 0.625, 95% CI: 0.437–0.893)
were found to be predictive for the MCID in all OA
patients (P = 0.010) (Table 5).

4. Discussion
Advanced stage OA is a chronic disease associated with
progressive cartilage degeneration. Known triggers of OA
include mechanical factors, age, and inflammation [15]. In
recent years, neither systemic nor intraarticular medical
treatment is effective in stopping the progression of OA
[15]. Surgical treatment is the last resort in patients with
OA.
Several studies have focused on factors in the
progression of OA in the elderly population. Kevorkian
et al. [16] showed that the expression of ADAMTS1,
ADAMTS5, ADAMTS9, and ADAMTS15 genes was
significantly decreased and that the expression of
ADAMTS16, ADAMTS2, ADAMTS14, and ADAMTS12
genes was increased in OA cartilage, compared to normal
cartilage. Naito et al. [17] demonstrated that ADAMTS4
might play an important role in the degradation of
aggrecan in human osteoarthritic cartilage. In our study,
we found no significant differences in synovial fluid
ADAMTS4 levels of stage 3 and stage 4 OA patients.
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Table 2. Best cutoff value, sensitivity, specificity, and AUC (95%Cl) of synovial fluid ADAMTS9 in OA.

Synovial fluid ADAMTS9 (ng/mL)

Cutoff

Spe %

Sen %

AUC (95 % CI)

P-value*

5.54

71%

55%

0.666 (0.549–0.783)

0.009

AUC; Area under curve, ADAMTS9; A disintegrin and metalloproteinase with thrombospondin motif 9.
Table 3. Clinical and laboratory parameters according to the response of the WOMAC score percentage in stage 3 OA patients.
WOMAC score percent
change <18%

WOMAC score percent
change ≥18%

P-value*

Age (years)

63.32 ± 7.32

60.50 ± 5.30

0.208

Smoking

6 (21.4%)

1(7.1%)

0.242

Synovial fluid ADAMTS4 (pg/mL)

128.79 ± 28.47

127.95 ± 27.40

0.928

Synovial fluid ADAMTS9 (ng/mL)

6.43 ± 2.01

5.04 ± 1.44

0.026

Hypertension and cardiovascular diseases

4(14.3%)

3 (21.4%)

Diabetes

1 (3.6%)

3 (21.4%)

No additional diseases

23 (82.1%)

8 (57.1%)

Concomitant
diseases

0.122

*; a P-value of < 0.05 is considered statistically significant. Independent sample t-test, P-value: Statistically significant difference between
WOMAC score percent change <18% and WOMAC score percent change ≥18% in stage 3 OA patients, ADAMTS4; A disintegrin
and metalloproteinase with thrombospondin motif 4, ADAMTS9; A disintegrin and metalloproteinase with thrombospondin motif 9,
WOMAC score; Western Ontario and McMaster Universities Osteoarthritis Score.
Table 4. Clinical and laboratory parameters according to the response of the WOMAC score percentage in stage 4 OA patients.
WOMAC score percent
change <18%

WOMAC score percent
change ≥18%

P-value*

Age (years)

68.08 ± 6.04

67.00 ± 5.06

0.548

Smoking

6 (24.0%)

2 (11.8%)

0.282

Synovial fluid ADAMTS4 (pg/mL)

127.47 ± 28.99

138.27 ± 43.47

0.339

Synovial fluid ADAMTS9 (ng/mL)

5.22 ± 1.42

4.60 ± 1.11

0.139

Hypertension and cardiovascular diseases

6 (24%)

5 (29.4%)

Diabetes

3 (12%)

1(5.9%)

No additional diseases

16 (64%)

11(64.7)

Concomitant
diseases

0.774

*; a P-value of <0.05 is considered statistically significant. Independent sample t-test, P-value: Statistically significant difference between
WOMAC score percent change <18% and WOMAC score percent change ≥18% in stage 4 OA patients, ADAMTS4; A disintegrin
and metalloproteinase with thrombospondin motif 4, ADAMTS9; A disintegrin and metalloproteinase with thrombospondin motif 9,
WOMAC score; Western Ontario and McMaster Universities Osteoarthritis Score.

However, the ADAMTS9 levels in the synovial fluid of
stage 4 OA patients were significantly lower than those of
stage 3 OA patients. Also, the WOMAC score in stage 4 OA
group was significantly lower than in the stage 3 OA group.
Pretreatment WOMAC scores were higher in the stage 3
OA group when compared with the stage 4 OA group,
possibly pointing out the ongoing cartilage degeneration.
In human chondrocyte cell lines, Coughlan et al. [10]
showed that both ADAMTS5 and ADAMTS9 appeared to
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be important in cartilage ECM formation and turnover,
and that depletion of ADAMTS5 and ADAMTS9 will
lead to improved ECM formation and neocorticalization.
Yaykasli et al. [11] demonstrated that leptin increased the
expression of ADAMTS4, ADAMTS5, and ADAMTS9
genes and cartilage degeneration in human chondrocytes.
Yang et al. [18] revealed abnormal increases in Cysteinerich protein 61(Cyr61) and ADAMTS4 protein levels in
OA tissues and chondrocytes. In the same study, Cyr61
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Table 5. Regression analysis for the prediction of poor treatment success in all
advanced stage OA patients.
WOMAC score percent change (≥18%)
OR (95 % CI)

P-value*

Age (years)

0.967 (0.905–1.034)

0.324

Smoking

2.732 (0.706–10.572)

0.146

Synovial fluid ADAMTS4 (pg/mL)

1.005 (0.991–1.020)

0.447

Synovial fluid ADAMTS9 (ng/mL)

0.625 (0.437–0.893)

0.010

Concomitant diseases

0.568 (0.221–1.464)

0.242

*; a P-value of <0.05 is considered statisticallysignificant.ADAMTS4; a
disintegrinandmetalloproteinasewiththrombospondin motif 4, ADAMTS9;A
disintegrin and metalloproteinase with thrombospondin motif 9, WOMAC score;
Western Ontario and McMaster Universities Osteoarthrtis Index.

Table 6. Regression analysis for the prediction of poor treatment success in stage 3 and stage 4 OA patients, respectively.
WOMAC score percent change (≥16%)
Stage 3

Stage 4

OR (95 % Cl)

P-value*

OR (95% CI)

P-value*

Age (years)

0.937 (0.848–1.036)

0.206

0.966 (0.864–1.079)

0.538

Smoking

3.545 (0.383–12.817)

0.265

2.368 (0.417–13.461)

0.331

Synovial fluid ADAMTS4 (pg/mL)

0.999 (0.976–1.023)

0.926

1.009 (0.991–1.027)

0.332

Synovial fluid ADAMTS9 (ng/mL)

0.602 (0.372–0.974)

0.039

0.651 (0.365–1.163)

0.147

Concomitant diseases

0.290 (0.069–1.216)

0.090

1.031 (0.285–3.735)

0.963

*; a P-value of <0.05 is considered statistically significant. ADAMTS4; A disintegrin and metalloproteinase with
thrombospondin motif 4, ADAMTS9;A disintegrin and metalloproteinase with thrombospondin motif 9, WOMAC
score; Western Ontario and McMaster Universities Osteoarthrtis Score.

reduced ADAMTS4 protein expression in chondrocytes,
and Cyr61 interacted with ADAMTS4 to affect OA
progression. Stanton et al. [19] found no significant
phenotypic abnormalities in ADAMTS4 and ADAMTS5
knockout mice. Still, they found a significant reduction
in the severity of surgically induced OA in ADAMTS5
knockout groups compared with ADAMTS4 knockout
groups [19]. The present study demonstrates the prediction
of intraarticular treatment success in stage 3 OA patients
with synovial fluid ADAMTS9 levels. Intraarticular steroid
injection was ineffective in stage 4 OA patients due to the
severity of cartilage degeneration.
In conclusion, we think that ADAMTS9’s low level
of synovial fluid is significant in the stage 3 group where
cartilage degeneration is continuing, and is meaningless in
the stage 4 group where cartilage has wholly degenerated,

there is no longer any extracellular matrix structure
and there will be no regeneration. With this result, the
significantly low level of ADAMTS9 may be related to the
fact that intraarticular or systemic treatments will still be
effective due to the ECM protease in the synovial fluid of
stage 3 OA patients.
The limitations of our study are mainly the lack of
evaluation of other proteases and proteoglycans, which
are risk factors of OA, a small number of patients and
the controls had a history of joint injury and had been
operated upon the knee for different reasons. The lack of
a control group and early-stage OA is the limitation of
the study. WOMAC 20,50, and 70 indexes could not be
obtained due to the limited number of patients. The fact
that no questionnaire related to the psychosocial status of
patients has been conducted is another limitation of our
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study. Further prospective studies in larger cohorts are
needed to validate the results of the present study.
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